BSX icon

Boston Scientific

102.87 USD
+0.13
0.13%
At close Apr 30, 4:00 PM EDT
After hours
104.12
+1.25
1.22%
1 day
0.13%
5 days
3.88%
1 month
1.97%
3 months
-0.16%
6 months
22.48%
Year to date
15.09%
1 year
43.13%
5 years
174.47%
10 years
477.27%
 

About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Employees: 53,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 13 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

154% more first-time investments, than exits

New positions opened: 211 | Existing positions closed: 83

25% more repeat investments, than reductions

Existing positions increased: 603 | Existing positions reduced: 482

11% more funds holding in top 10

Funds holding in top 10: 35 [Q3] → 39 (+4) [Q4]

10% more capital invested

Capital invested by funds: $109B [Q3] → $120B (+$10.8B) [Q4]

8% more funds holding

Funds holding: 1,372 [Q3] → 1,479 (+107) [Q4]

2.23% more ownership

Funds ownership: 88.28% [Q3] → 90.51% (+2.23%) [Q4]

13% less call options, than puts

Call options by funds: $797M | Put options by funds: $912M

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$112
9%
upside
Avg. target
$120
16%
upside
High target
$130
26%
upside

13 analyst ratings

13 positive
100%
neutral
0%
negative
0%
Barclays
Matt Miksic
48% 1-year accuracy
20 / 42 met price target
22%upside
$125
Overweight
Maintained
25 Apr 2025
Needham
Mike Matson
36% 1-year accuracy
44 / 121 met price target
12%upside
$115
Buy
Maintained
24 Apr 2025
RBC Capital
Shagun Singh
49% 1-year accuracy
33 / 68 met price target
17%upside
$120
Outperform
Maintained
24 Apr 2025
Truist Securities
Richard Newitter
57% 1-year accuracy
29 / 51 met price target
14%upside
$117
Buy
Maintained
24 Apr 2025
Evercore ISI Group
Vijay Kumar
30% 1-year accuracy
12 / 40 met price target
9%upside
$112
Outperform
Maintained
24 Apr 2025

Financial journalist opinion

Based on 35 articles about BSX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Earnings Season: 3 Companies Raising Guidance
Raising guidance? In this uncertainty?
Earnings Season: 3 Companies Raising Guidance
Positive
Seeking Alpha
1 day ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Positive
Investors Business Daily
1 day ago
SAP Stock And Two Others Outperform S&P 500; One Is In A Buy Zone
SAP stock broke out of a double-bottom base Monday. SAP, an aerospace stock and a medical device maker all show this winning stock trait.
SAP Stock And Two Others Outperform S&P 500; One Is In A Buy Zone
Positive
Zacks Investment Research
2 days ago
EMEA Growth & Product Launches to Support Boston Scientific Stock
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
EMEA Growth & Product Launches to Support Boston Scientific Stock
Positive
Zacks Investment Research
2 days ago
Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?
Positive
Investors Business Daily
4 days ago
MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points
Stocks near buy points include Charles Schwab, German software leader SAP and MercadoLibre, the so-called Amazon of Latin America,
MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points
Positive
Zacks Investment Research
5 days ago
Here is Why Growth Investors Should Buy Boston Scientific (BSX) Now
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is Why Growth Investors Should Buy Boston Scientific (BSX) Now
Positive
Zacks Investment Research
5 days ago
Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know
Positive
Zacks Investment Research
5 days ago
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock
Positive
Zacks Investment Research
5 days ago
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Charts implemented using Lightweight Charts™